Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 50 versus DEXTROSE 50 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 50 versus DEXTROSE 50 IN PLASTIC CONTAINER.
DEXTROSE 50% vs DEXTROSE 50% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intravenous administration of 50% dextrose solution rapidly elevates blood glucose levels by providing exogenous glucose, which is taken up by cells via glucose transporters and metabolized to produce adenosine triphosphate (ATP), thereby correcting hypoglycemia.
Dextrose is a monosaccharide that serves as a source of energy for the body. It is rapidly metabolized to produce glucose, which is essential for cellular metabolism. Intravenous administration increases blood glucose levels, providing calories and correcting hypoglycemia.
For hypoglycemia: 25 grams (50 mL of 50% solution) intravenous bolus, may repeat once if needed. For insulin-induced hypoglycemia: 25-50 grams intravenously.
Intravenous administration of 25 g (50 mL of 50% solution) for hypoglycemia; may repeat as needed. For hyperkalemia, administer 25 g (50 mL) with 10 units of regular insulin intravenously. Continuous infusion for parenteral nutrition is 5-25 g per liter of total nutrient admixture, rate based on glucose tolerance.
None Documented
None Documented
2-4 hours (exogenous glucose); in critically ill patients or hyperglycemic states, half-life may be prolonged due to impaired glucose utilization.
Terminal elimination half-life of glucose is approximately 1.5-2 hours in normoglycemic individuals; prolonged in renal or hepatic impairment or hyperglycemic states.
Primarily eliminated by cellular metabolism to carbon dioxide and water; renal excretion of unchanged glucose occurs when plasma concentration exceeds renal threshold (approximately 180 mg/dL), accounting for <5% of elimination under normoglycemic conditions.
Excreted primarily via renal routes: ~10% unchanged in urine; remainder metabolized to carbon dioxide and water, exhaled via lungs. Fecal elimination negligible.
Category C
Category C
Intravenous Hypertonic Dextrose Solution
Intravenous Hypertonic Dextrose Solution